Quick Summary:
In a rapidly evolving healthcare industry where precision and efficacy are paramount, understanding the nuances of the global Myeloproliferative Disorders Drugs Market is a necessity for business executives aiming to stay ahead of the curve. Our comprehensive research report on this market, currently valued at an estimated US$9.3 Billion in 2022, provides insightful analysis and detailed insights into the future trajectory of this market, which is projected to reach around US$12.9 Billion by 2030.
Key features of this report include sharp analysis of key market segments like Ph+ Chronic myelogenous leukemia (CML), which is forecasted to record a 3.5% CAGR and reach US$9.2 Billion by 2030. Additionally, it offers a robust evaluation of emerging markets, with special focus on China, poised to grow at 7.3% CAGR. With a sweeping overview of market competitiveness and presence across various geographies, our report provides valuable information for decision-makers and strategists.
Global Myeloproliferative Disorders Drugs Market to Reach $12.9 Billion by 2030
The global market for Myeloproliferative Disorders Drugs estimated at US$9.3 Billion in the year 2022, is projected to reach a revised size of US$12.9 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2022-2030. Ph+ Chronic myelogenous leukemia (CML), one of the segments analyzed in the report, is projected to record 3.5% CAGR and reach US$9.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ph- Myeloproliferative Neoplasms (MPNs) segment is readjusted to a revised 6.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $2.5 Billion, While China is Forecast to Grow at 7.3% CAGR
The Myeloproliferative Disorders Drugs market in the U.S. is estimated at US$2.5 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.9% and 3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.Select Competitors (Total 34 Featured) -
- Bristol-Myers Squibb
- Inctye
- Novartis
- Pfizer
- Takeda
- Teva
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Myeloproliferative Disorders Drugs?
What is the growth rate of the Global Market for Myeloproliferative Disorders Drugs?
What is the forecasted size of the Global Market for Myeloproliferative Disorders Drugs?
Who are the key companies in the Global Market for Myeloproliferative Disorders Drugs?
| Report Attribute | Details |
|---|---|
| No. of Pages | 89 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 9.3 Billion |
| Forecasted Market Value ( USD | $ 12.9 Billion |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Bristol-Myers Squibb
- Inctye
- Novartis
- Pfizer
- Takeda
- Teva
